

Respiratory Therapy
Pulmonary, Allergy, & Critical Care Medicine

SUBJECT	CONSULT SERVICE HANDBOOK
DATE ISSUED	
AREAS AFFECTED	All Hospital Floors
PREPARED BY	Lucy Kester
APPROVAL	James K. Stoller, M.D.
REVISION DATES	May 2004, 2007, 2008

#### RESPIRATORY THERAPY CONSULT SERVICE

A survey conducted at The Cleveland Clinic Foundation in 1987 demonstrated that approximately 25% of Respiratory Therapy treatments were ordered inappropriately, that is, either there were no indications for therapy or the wrong therapy was selected. In an attempt to remedy this situation and improve patient care, the Respiratory Therapy Consult Service has been created to assist the physician with evaluating patients' respiratory care needs, determining the indications for respiratory therapy, and selecting the appropriate modalities.

This booklet is designed to inform you about the procedure for ordering a Respiratory Therapy Consult, the process (algorithms) used to determine specific therapies, the evaluation form used in the charts, and the re-evaluation process. If you have any questions regarding this service please feel free to ask any of the therapists or call Respiratory Therapy at 45797 and talk with a Supervisor or the Education Coordinator.

# RESPIRATORY THERAPY CONSULT SERVICE NEW EVALUATIONS

- A. A physician may write an order for a Respiratory Therapy Consult by,
  - 1. Writing on a Physician Order Form
  - 2. Using the Computer Physician Order Entry (CPOE) system
- B. Respiratory Therapy Consults are provided for all patients for whom respiratory therapy orders are written with the exceptions of:
  - 1. Post-Cardiac surgery patients
  - 2. Patients admitted to the short stay unit, unless they are admitted to the hospital.
- C. When a physician writes an order for a Respiratory Therapy Consult:
  - 1. An evaluation will be performed according to the Respiratory Therapy Consult Service (RTCS) standardized evaluation guidelines and a care plan written.
  - 2. Discussion between the physician and a Respiratory Therapist concerning the rationale for therapy is encouraged.
  - 3. The RTCS care plan (which will include physician orders for specific medications) will be followed until the indications for therapy are resolved.
  - 4. During the course of therapy, the physician will be called if the patient's clinical status worsens, or if an adverse event occurs.
  - 5. Physician written medication orders will be followed for 24 hours and the patient reassessed. If therapy is not indicated at this time, the physician will be contacted and asked to discontinue treatment.
  - 6. Short-term orders (orders < 24 hour duration) for a single modality (e.g., oxygen, aerosol) will be followed without generating a Respiratory Therapy Consult Service (RTCS) evaluation.

For questions:

Please PAGE #23406 or call ext. 45797

#### **RE-EVALUATIONS**

- A. Daily assessment will be made by the Therapist treating the patient and if changes are indicated, they will be presented during Consult Rounds with a Supervisor or a Clinical Specialist. If the changes are in accordance with the Consult Service guidelines/algorithms, they will be instituted at this time.
- B. Changes will be recorded in our management information system (MediServe) and will be available for review in the hospital EPIC system.

#### **CARE PLAN PROCESS**

#### STEP 1

Perform patient evaluation using evaluation guidelines. Determine appropriate Triage number.

## STEP II

Determine indications and related therapy using indication guideline sheet.

#### STEP III

Follow appropriate therapy flow sheet (algorithm):

a. aerosol therapy

b. hyperinflation therapy

c. bronchopulmonary hygiene

d. oxygen therapy

#### **STEP IV**

Write care plan to include:

a. therapy

b. frequency

c. indications

d. objectives

# THE CLEVELAND CLINIC FOUNDATION DEPARTMENT OF PULMONARY DISEASE RESPIRATORY THERAPY EVALUATION

Date: /	./			Age		ιŪ	_							
Time:	ne:Ht.:						_							
Diagnosis:	<b>A</b>						-							
						-				IMPRIN	IT/LABEL			
Respiratory Thera	apist						_							
			Т	F	т —	ASSE				_	T			
Clinical Findings		0	×		х			х	3	x	-	4	х	Points
Pulmonary Status	(–) Histo	ory		Smoking history		Smoking history	g		Pulmonary impairment		Severe or chronic with			
	(–) Smo	king		< 1 pk a day		≥1 pk a	day		(acute or chronic			erbation		
Surgical	No surg	jery		General	l	Lower abdomi	aal		Thoracic			acic with		
Status				surgery		abdomii	ıaı		or upper abdominal		dise	nonary ase		
Chest	Clear or			Chronic		Infiltrate			Infiltrations in	Τ	Infilt	rate +	П	
X-ray	not indi	cated		changes or x-ray pending		atelecta pleural	sis or		more than one lobe		atele ± ple	ectasis		
				x ray perialing		effusion	S				effus			
LAB TEST: Date	e:/ _	/	-1	Date:			pł	1	PaCO <sub>2</sub>	Pa(	02	HCO <sub>3</sub>	9	Sat / FiO <sub>2</sub>
WBC H	lb F	Plts	-	/_		/								
PULMONARY F	UNCTION	TEST:		SpO2 / FiO2	2	Vita	al Signs	3:	HR		BP_		RR.	
Minimal Pred. \	/C					1								
VC P	PEAK FLO	N				<sub>TE</sub>	MPER.	ΑΤΙ	JRE (24 hr max)					
				DATIE	NI.	T ASSE				***				
Clinical Finding	8	0	×		x			х	3	x		4	x	Points
Respiratory		pattern	Ť	Increased	r	Dyspnea		Ê	Decreased vital	Î	1000 0.00	ere SOB,	H	1 Onto
Pattern	RR 12-	20		RR 21–25	l	exertion			capacity*		use		П	
					irregular pattern				RR 31-35		mus	essory cles		5
,			L		L	RR 26-3				Ļ	RR:		Ш	
Mental Status	Alert, or coopera			Lethargic, follows		Confuse does not			Obtunded		Com	atose		Si
Otatus	coopera	alive		commands		commar								
Breath	Clear to			Decreased		Decreas			Crackles in the			ezing		
Sounds Cough	ausculta Strong,		┢	unilaterally Strong,	<u> </u>	bilateral Weak, n		_	bases Weak,	╁		or rhonchi pontan-	H	
Effectiveness	spontar	neous,		productive	İ	producti			productive or		eous	cough		
	non-pro	ductive			l				weak with rhonchi			ay require oning		
Level of	Ambula	tory	T	Ambulatory	T	Tempora	arily		Bed rest, able to	T		rest,	H	
Activity				with	l	Non-			position self			ole to		
Oxygen required	d	No	╁	assistance	┞	ambulat			> 50%	╀	posi	tion self 100%	Н	
for SpO <sub>2</sub> ≥92%		ygen		1-3 Liters		4-6 Li	ters		<100%			100 /6		
Total Points														
*VC ≤ to minimal	predicted:					ldeal Bod						a e innere 5. <del>3.5</del> .	<u> </u>	
	(males: 50 + 2.4 x inches > 60)													
(females 45 + (2.4 x inches > 60)  Multiply above ideal body wt. x 15cc for min. pred. VC														
TRI	AGE 1	TRIA					RIAGE				1		Γ	
	>20						(6–10		(0-5)	,				
I													T	RIAGE#

PWO 7197 Rev. 7/06

# **MINIMUM PREDICTED VOLUMES**

	Women	
<u>hgt</u>	<u>ibw</u>	<u>pred</u>
4'9"	38	.570
4'10"	40.4	.606
4'11"	42.6	.639
5'0"	45	.675
5'1"	47.4	.711
5'2"	49.8	.747
5'3"	52.2	.783
5'4"	54.6	.819
5'5"	57	.855
5'6"	59.4	.891
5'7"	61.8	.927
5'8"	64.2	.963
5'9"	66.6	.999
5'10"	70	1.05
5'11"	72.4	1.08
6'0"	74.8	1.12
	Men	
<u>hqt</u>	ibw	pred
5'5"	62	.930
5'6"	64.4	.968
5'7"	66.8	1.00
5'8"	69.2	1.03
5'9"	71.6	1.07
5'10"	74	1.11
5'11"	76.4	1.14
6'0"	78.8	1.18
6'1"	81.2	1.22
6'2"	83.6	1.25
6'3"	86	1.29
6'4"	88.4	1.32
6'5"	90.8	1.36
6'6"	93.2	1.40
6'7"	95.6	1.43
6'8"	98	1.47

#### **INDICATION GUIDELINES**

#### **Indications**

#### A. Aerosol Therapy

- 1. bronchospasm (bronchodilator)
- 2. history of bronchospasm (beta agonist, anti-cholinergic, steroid)
- 3. home regimen
- 4. physician order
- 5. proteinaceous secretions (mucolytic)
- 6. inflammation, mucosal edema (steroid, vasoconstrictor)

#### B. **Bronchopulmonary Hygiene**

- 1. productive cough
- 2. history of mucus producing disease
- 3. rhonchi on auscultation
- 4. patient is unable to deep breathe and cough spontaneously

## C. **Hyperinflation Therapy**

- 1. atelectasis
- 2. upper abdominal or thoracic surgery, or COPD & surgery
- 3. restrictive disease associated with quadriplegia and, or dysfunctional diaphragm

## D. Oxygen Therapy

- 1.  $Pa0_2 < 65$  torr on room air
- 2.  $Sp0_2 < 92\%$  on room air
- 3. clinical signs of hypoxemia\*
- 4. chest pain with cardiac history
- 5. home O<sub>2</sub>
- 6. post-op care

NOTE: For acute symptoms of hypoxemia or bronchospasm associated with tachycardia, tachypnea, or decreased oxygen saturation, treat the patient with the appropriate oxygen device or a bronchodilator via a SVN first, before completing the entire evaluation process. Bronchodilators may be given q2-q4, ATC and PRN x 24 hours until symptoms subside. In such an acute situation, any immediate physician orders will be followed until a complete RTCS evaluation has been made.

<sup>\*</sup>Increased respiratory rate, increased pulse rate, diaphoresis, confusion, cyanosis

## FREQUENCIES (Guidelines)

<b>A.</b> 1.	Aerosols Q2 to Q4, ATC, PRN*	Indications Severe SOB, wheezing, unable to sleep Moderate SOB, wheezing	Triage 1 &2
2.	QID & PRN at night (Q 12 hr. for Serevent)	Hx of asthma, mild wheezing, or facilitate secretion removal	3
3. <b>B.</b> 1.	PRN Q 6 Bronchopulmonary Hygi Q4 ATC	Intermittent wheezing iene Copious secretions, SOB, unable to sleep, su	4
2.	QID & PRN at night	mucus plug Moderate amounts of secretions	1 2
3.	TID	Small amounts of secretions + poor cough,	0
4.	Q shift WA	history of secretions Patient unable to deep breathe & cough spontaneously	3 4
<b>C.</b> 1.	Hyperinflation Technique Q4 WA & PRN		1
2.	QID	Patients at high risk for, or with persistent atelectasis	2
3.	TID	Patients at risk for developing atelectasis	3
4.	Q shift, WA	Prevention of atelectasis	4
5.	Instruct, D/C, video	Patients able to perform well on their own	5
<b>D.</b> 1.	follow-up Pulse Oximetry *** Continuous until stable, then Q4 + PRN in between	Unstable patients n	1
2.	QID, + PRN in between	Low Pa02 with variances	2
3.	PRN	To titrate Fi02	3, 4, or 5
4.	Daily x 2 days	If, after titration, Sp02 remains at least 92%, D/C pulse oximetry	4 or 5

\*If patient requires more frequent aerosols, please contact supervisor or work leader. Note:

PRN orders (except for oximetry or suctioning) must always accompany a frequency - e.g. Aerosol Q4 WA and PRN.

<sup>\*\*</sup>IS and PEP must be performed by patient on their own Q 1 hr WA.

\*\*\*Patients not on 0₂, with Sp0₂ ≥ 92% should have pulse oximetry DC'd and restarted only when clinical signs indicate a need for 0₂.

#### THE CLEVELAND CLINIC FOUNDATION **DEPARTMENT OF PULMONARY DISEASE**

# **RESPIRATORY THERAPY CONSULT/EVALUATION**

Your patient has been evaluated by the Respiratory Therapy																
Consult Service. Based on the patient's clinical indicators,																
the Care Plan designated below will be implemented.							IMPRINT/LABEL									
Day	ta of Fuelustian			Allergies												
Tim	ne of Evaluation			Diagnos		CLINICAL INC	ICA	TIONS								
Do	et Theresia Sur	cor	v Pro	tocal D		CLINICAL INL	ICA	TIONS								
	st Thoracic Sur Aerosol Therapy	ger		cho/Pulmonar	у	Hyperinflation		Oxygen Therapy		Respiratory Monitoring	,	Suctioning				
	bronchospasm		produ	uctive cough		atelectasis		SpO2 < 92% or PaO2 < 65 torr		O2 titration (pulse ox.)		presence of secretions				
	history of bronchospasm			chi on ultation		upper abdominal o thoracic surgery, o	ſ	on room air		unstable res	р. 🗆	unable to cough				
	home regimen		histo			COPD & surgery restrictive disease	u	clinical signs of hypoxemia	П	status ABGs (SpO)	) г	effectively				
	physician order			. disease	J	associated with quadriplegia and,		chest pain with cardiac history	J	<92% on roo	om	airway				
	proteinaceous secretions	u	to de	nt unable ep breath		or dysfunctional diaphragm		home 02		SpO2/FiO2						
	inflammation/ mucosal edema			cough taneously				post-op care		Vital Capac	ity					
						CARE P	LAN									
Aei	rosol Therapy											Frequency				
								DPI DNe	b	□ MDI						
								DPI DNe	b	□ MDI						
						,	C	DPI DNe	b	□ MDI		J. Carlotte				
	oncho/Pulmonary giene	у		pos. drainage		percussion/vibra	tion	coughing te	chni	ques						
	perinflation			incentive spirometry		CPAP, PEP		□ IPPB				+ 1111				
Ox	ygen Therapy			FIO2 %		liters/minute		□ Device								
Мо	nitoring			pulse oximetry		ABGs		☐ resp. mecha	anics	5						
Suc	ctioning			nasal tracheal		tracheal										
Coi	mments									3						
PR	INT NAME:															
SIC	GNATURE:					7			_ B	EEPER NO						
	re plan modifica				se to	changes in the pa	tient	s' condition, are	ava	ailable for yo	ur re\	view through the				
												158974 Rev 7/04				


#### **AEROSOL THERAPY\***

#### Indications:

Current, or history of bronchospasm Inflammation, mucosal edema Proteinaceous secretions

#### Type of Medication:

**Bronchodilator** Steroid, vasoconstrictor Mucolytic



- Bronchodilators If the patient lacks any prior history of lung disease, is not using bronchodilators at home, and has no wheezing when receiving the bronchodilator less often that q 4 hours, the
- the point that the patient is able to clear them with a cough, the mucolytic may be discontinued.
- Anti-inflammatory Medications If the patient lacks any prior history of lung disease, is not using an inhaled anti-inflammatory medication at home, and lacks wheezing by examination or by history for at least 24 hours, the anti-inflammatory medication can be discontinued.


(Discontinuation requires a physician order.)

#### \*\*Appropriate PAP devices:

- PEP (i.e. Thera-PEP)
- Measured PEP (i.e. EZ-PAP)
- Oscillatory device (i.e. Acapella)
- Intermittent CPAP

# **Bland Aerosol**


(Thick secretions)



#### \*Appropriate PAP devices:

- PEP (i.e. Thera-PEP)
- Measured PEP (i.e. EZ-PAP)
- Oscillatory device (i.e. Acapella)
- Intermittent CPAP

#### **ASTHMA MEDICATION**



- \* Albuterol may be given up to every 1-2 hours if needed. If the patient is unable to use an MDI effectively, use a small volume nebulizer.
- \*\* Symptomatic = wheezing, SOB, cough, exercise intolerance, RR > 21.
- \*\*\* If wheezing subsides and respiratory rate is < 21, decrease albuterol to 2 puffs QID.

## ADULT RESPIRATORY THERAPY CONSULT MEDICATION ORDER FORM

+										
+						_				
	THE CLEVELAND CLI	NIC FOUNDATION								)
+)	PHYSICIAN'			For sca			fix patient lab	el		
	RECORD ALL ALLERGIES AND	) INTOLERANCES: (U	Jpdate MyPractice	e)			within this o	outline	d box.	
	NO KNOWN ALLERGIES OR IN	JTOLEBANCES								
	DATE TIME	11 OLLIVAINOLS	USE BALLPOIN	Γ PFN ON	JI Y		Affix Patier	nt ID L		RDER#
		RESPIRATORY				DER FOR	М			
	Bronchodilators	SVN (small volume	MDI (metered dose	Inhala- tions	(dry	DPI y powdered inh		hala- ions	*Frequency	**PRN
	ß adrenergic	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	innaier)							
	Albuterol	2.5 ma 5.0 mg 15 mg times 1 hour continuous mg/hour continuous	90 mca	2						
+)	Salmeterol (Serevent®)	conunuous			50 m	ca		1		
	Epinephrine (Racemic®)	0.5 ml of 2.25% sol.								
	Anticholinergic	2.25% SOI.								
	Ipratropium bromide (Atrovent®)	0.5 ma	18 mcg	2						
	Tiotropium (Spiriva®)		_		18 m	cg		1		$\blacksquare$
	Anti-inflammatory									
	Cromolyn sodium (Intal®)	20 mg	800 mca	2						-
+)	Triamcinolone (Azmacort®)		100 mca	2						-
	Fluticasone (Flovent®)		44 mcg 110 mcg 220 mcg	2 2 2	50 m 100 r 250 r	ncg		1 1		
	Beclomethasone (QVAR®)		40 mca 80 mca	1						
	Budesonide (Pulmicort®)	0.25 ma 0.5 mg			90 m 180 r	ca Flexhaler nca Flexhale	er	1		
	Combination Meds									
+	Fluticasone/Salmeterol (Advair®)				100 50 Flut	250 50 ticasone/Salme	500 50 eterol	1		
	Albuterol/lpratropium (Combivent®)		103 mcg 18 mcg Albuterol Ipratropium	2						
	Mucolytic									
	Acetylcysteine (Mucomyst®)	10% 20%								
	Other:									
	** PRN indications	<u> </u>	1			Patient	Transfer:	Med	lication R	l eorder
	1 PRN / frequency - for interm 2 PRN / frequency - as used f 3 PRN / frequency - for stridor 4 PRN / other	ittent wheezing or home regimen		*		Frequer Stat Tre	ncy Changatment	ge	inistration S	
	4 PRN / other		PRN <sup>1</sup>	Daily	two times a	_	ree times a day	four times		
			WA <sup>2</sup>	-			ery 4 hours			
+)	Is this the patient's home regime		ATC <sup>3</sup>				ery 4 hours	every 2 hou		
	PRINT NAME	-	Ası	needed <sup>2</sup> W	/hile awake	Arou	und the clock			
	SIGNATURE	BEEPE	ER No. ———		_					
	Respiratory Therapist:		Date ———	— Time		— Pager	#	_	170520 5	201 9/07
									178532 F	ev. 8/07

#### **GUIDELINES FOR PRIMING MDIS**

DRUG NAME	# OF SPRAYS TO PRIME	WHEN TO REPRIME
Proventil HFA (albuterol)	4	after 2 wks of no use
ProAir HFA (albuterol)	3	after 2 wks of no use
Ventolin HFA (albuterol)	4	after 2 wks of no use, or if dropped
Atrovent HFA (ipratropium)	2	after 3 days of no use
Flovent HFA (fluticasone)	4	after 7 days of no use, or if dropped
Advair HFA	4	after 4 wks of no use, if dropped
(fluticasone/salmeterol)		only 2 sprays to reprime
Xopenex HFA (levalbuterol)	4	after 3 days of no use
Symbicort	2	after 7 days of no use, or if dropped
(formoterol/budesonide)		
Qvar HFA (beclomethasone)	2	after 7 days of no use
Combivent	3	after 24 hrs of no use
(ipratropium/albuterol)		
Azmacort (triamcinolone)	2	after 3 days of no use
Maxair (pirbuterol)	2	after 48 hrs of no use
Alvesco (ciclesonide)	3	after 10 days of no use
Aerospan HFA (flunisolide)	2	after 2 wks of no use

#### RECOMMENDED INSTRUCTIONS FOR DRY POWDERED INHALER USE

## <u>Pulmicort Flexhaler</u>- (budesonide)

Must be primed before 1<sup>st</sup> use. To prime, twist the brown grip in one direction & fully back in the opposite direction. Repeat once more. When loading a dose, flexhaler must be in the upright position (mouthpiece up).

## **Spiriva**-(tiotropium)

Do not press green piercing button more than once. Pierce with mouthpiece pointing up. Breathe in medication with the handihaler in the horizontal position.

## **Asmanex**- (mometasone)

No need to prime it. Hold inhaler in the upright (pink on bottom) position, twist cap off in counterclockwise direction. Inhale medication with inhaler in the horizontal position. Cap must be replaced to load the next dose. Cap will not come off if medication is gone.


## Advair (fluticasone/salmeterol), Flovent (fluticasone), Serevent (salmeterol) (Diskus)-


Place Diskus in horizontal position. Slide lever away until it clicks. Inhale the medication with the Diskus in the horizontal position. Tilting the Diskus will cause the medication to fall out. (the patient will not get any medication)

## **Foradil**-(formoterol)

Hold Aerolizer in the upright position. Push both buttons at the same time and only once. With the buttons facing left and right and the aerolizer in the horizontal position, inhale medication.

#### **BRONCHOPULMONARY HYGIENE (bph)**






and/or rhonchi can be cleared with cough.

#### HYPERINFLATION THERAPY

#### Indications:

- 1. Atelectasis
- 2. Upper abdominal or thoracic surgery, or COPD and surgery
- 3. Restrictive disease associated with quadriplegia or dysfunctional diaphragm




#### \*Appropriate PAP devices:

- PEP (i.e. Thera-PEP)
- Measured PEP (i.e. EZ-PAP)
- Oscillatory device (i.e. Acapella)
- Intermittent CPAP


Hyperinflation therapy will be discontinued when atelectasis has been resolved as evidenced by chest x-ray, and/or when the patient's  $SpO_2$  and respiratory rate return to normal  $(SpO_2 \ge 92\%)$  on room air) or baseline values for 2 consecutive treatments and breath sounds are clear.

#### **OXYGEN THERAPY**




- 2. Patients on less than 4 Lpm  $0_2$ , increase  $0_2$  as needed to achieve a Sp $0_2 \ge 92\%$  (max. 4 Lpm). If patient requires > 4 Lpm, go to Yes in this portion of algorithm and check an ABG.
- 3. Or no  $0_2$  if saturation is adequate on room air.

#### **OXYGEN THERAPY ASSESSMENT**



- \* For patients with diagnosed or R/0 angina or MI, continue low flow 0<sub>2</sub>. When 0<sub>2</sub> has been on standby longer than 48 hours, reassess.
- \*\* If patient required chronic use of supplemental 0<sub>2</sub> pre-op, prescribed liter flow in accordance with patient's previous baseline Sp0<sub>2</sub>.

#### **OXYGEN THERAPY TITRATION**



#### ARTERIAL BLOOD GAS MONITORING


#### **STANDARD ABG CRITERIA:**

Baseline ABG for new admissions (If not done previously)
Hemodynamic instability
Pre and Post extubation

#### \*\* Last ABG shows:

PH > 7.50, or pH < 7.30, PaC0 $_2$  > 55, Pa0 $_2$  < 60 torr and/or Sat. < 90%, HC0 $_3$  < 18 mEq/L (Unless prior criteria established) Cyanosis


Unexpected dysrhythmias
Unexpected change in mental status
RR > 35 for >15 minutes (in the absence of pulmonary disease)
RR < 6 bpm, paradoxical breathing
acute change in breath sounds




\*\* Draw ABG at least Q shift.


#### POST-OP THORACIC SURGERY PROTOCOL

(Exclude thoracic laparoscopic hiatal hernia procedures, mediastinoscopies, and lung biopsies)




#### POST-OP LUNG TRANSPLANT PROTOCOL






- \* Select appropriate PAP device (PEP, measured PEP, oscillatory device)
- \*\* Early ambulation is essential. Increase as tolerated.
- \*\*\*Use Bedside Spirometer for FEV<sub>1</sub> measurement.


#### POST-OP LUNG REDUCTION SUGERY PROTOCOL






- Appropriate PAP devices (PEP, measured PEP, oscillatory device) Early ambulation is essential. Increase as tolerated.

#### POST-OP HEART TRANSPLANT PROTOCOL



- 1. Medicated aerosol criteria: bronchospasm, history of bronchospasm
- 2. bph criteria: secretions, rhonchi that do not clear with cough
- 3. Maintain  $SpO_2 \ge 92\%$ .
- \* Appropriate PEP device (PEP, measured PEP, oscillatory device)
- \*\* Early ambulation is essential. Increase as tolerated.



- 1 Considerations for Ventilation
- tachypnea/bradypnea
- increasing oxygen requirement
- increasing PaCO2
- decreased alertness

#### 2 Considerations for NIV

- COPD with initial respiratory failure
- heart failure

- 3 Criteria to Pass Wean Screen
- reversal of underlying causes
- presence of spontaneous breath efforts
- PaO2 > 60 torr or SaO2 > 90% on FiO2 ≤ 0.40
- pH > 7.30
- PEEP ≤ 8 cmH2O
- RR ≤ 35 breaths/min
- HR <140 beats/min
- systolic BP between 90 and 160
- Levophed < 5 ug/min
- temperature < 38.5 degrees C

Presence of all criteria required to pass

- \* Conditions of SBT
- PEEP = 5 cm H2O
- pressure support = 5 cm H2O
- trial to last 60 minutes

#### 4 Criteria to Pass SBT

- PaO2 > 60 torr or SaO2 > 90% on FiO2 ≤ 0.40
- change in pH < 0.10
- change in PaCO2 < 10 mmHg
- RR ≤ 40 for > 50 minutes
- drop in systolic PB < 20%
- systolic BP > 80

Presence of all criteria required to pass

#### 5 Criteria for Extubation

- suctioning less frequent than Q2 hours
- adequate cough
- follows commands (eg "close eyes")

Presence of all criteria required to pass

## NPPV (BiPAP) Therapy Assessment and Management

#### Indications:

Thoracic cage deformities Neuromuscular disease Idiopathic hypoventilation Respiratory distress Hypercapnic COPD Obstructive sleep apnea Obesity hypoventilation

#### Exclusion Criteria:

Respiratory arrest Cardiorespiratory instability Uncooperative patient Recent facial, esophageal, or gastric surgery High aspiration risk Inability to protect airway Fixed anatomic abnormalities of the nasopharynx Copious secretions

#### Assessment:

- Cause of respiratory distress
- Hemodynamically stable (systolic >90 mmHg)
- 3.  $pH \ge 7.28$
- 4. Assess level of consciousness
- Protect airway
- Secretions

- Critical Factors for Success of NPPV: 1. Cooperative patient
  - 2. Hemodynamically stable
  - 3. Ability to protect the airway
  - 4. No excessive secretions


#### Advantages of NPPV:

- 1. Patient comfort
- 2. Airway defense maintained
- 3. Ability to eat and speak
- 4. Endotracheal intubation complications avoided
- 5. Lower risk of nosocomial pneumonia

#### Disadvantages of NPPV:

- 1. Need cooperative patient
- 2. Inability to suction airway
- 3. Facial trauma
- 4. Gastric distention

#### NPPV (BiPAP) Management



#### **HOME O2 QUALIFICATION**

## I. Qualifying Conditions

- A. Chronic Cardio- Pulmonary Diagnosis
  - 1. example: COPD/ Asthma/ Lung Cancer/IPF/
  - 2. CHF/Pulmonary hypertension
- B. Hypoxemia as defined by:
  - 1. ABG results: PaO2 < 56, and/or, SaO2 <89% on room air.
  - 2. Pulse oximetry results: SpO2 <89% on room air.

#### II. Medicare/Private Insurance Carrier

- A. Home O2 qualification
  - 1. SpO2, at rest, of <89%
    - a. always check more than one site
    - b. check a manual pulse
    - c. document on desaturation study form
  - 2. ABG at rest with PaO2 of <56 and /or SaO2 of <89% on room air
    - a. SpO2 may be used to determine O2 requirements
  - 3. Either ABG or Pulse oximetry results may be used for qualification
    - a. qualifying studies must be done within 48 hours of discharge home
    - b. patients going to another facility after leaving the hospital must be qualified for home oxygen at that facility before discharge home.
- B. Determining needed O2 requirement
  - 1. Determine lowest O2 level that will maintain an SpO2 of ≥ 92% (not to exceed 94%) at rest
  - 2. Ambulate patient on resting O2 requirement for six minutes or as tolerated.
    - a. SpO2 on exertion should be > 90%
    - b. Document the SpO2, the required liter flow and the distance traveled before desaturation.
    - c. also document the resting SpO2 on the liter flow required to maintain an SpO2 of > 90% on exertion
- C. Exertional Home O2
  - Patients with a chronic pulmonary diagnosis whose resting SpO2 is >88% but desaturate
    - to < 89% with exertion
  - 2. A desaturation study is required
    - a. ambulate patient at a normal pace for six minutes or as tolerated
  - 3. Determine lowest O2 level required to maintain an SpO2 of >88% to <93% with exertion
    - a. document exertional SpO2 and liter flow required
    - b. document a resting liter flow on the exertional liter flow

#### Medicaid (Ohio Department of Welfare) Patients III.

A. Follow Medicare guidelines

#### IV. **Documentation for all patients**

- A. Fill out Desaturation study form ( see example)
  a. white copy goes in patient's chart
  b. yellow copy goes to the department
  c. document all patient education on this form
- B. Follow Respiratory Therapy Section documentation procedure